What Are Cholesterol Values, HDL, LDL and Triglycerides? What Should Levels Be by Age?

“My LDL cholesterol is 110—is that normal?”, “Does high HDL balance bad cholesterol?”, “Is rising cholesterol natural as I age?” These are common questions after blood testing. Reading a laboratory report correctly requires more than checking red-marked lines.

A reference range is not the same as a treatment target. In someone with a previous heart attack, an LDL level marked normal may exceed the target. Conversely, one borderline value does not mean everyone needs medication immediately. This guide explains the distinction using the 2026 ACC/AHA and 2025 ESC/EAS updates. [3, 7, 9]

What Are Cholesterol, HDL, LDL and Triglycerides?

Cholesterolis a fat-like sterol used to build cell membranes, steroid hormones and bile acids. The body produces much of it and also obtains it from food. Being necessary does not make every blood level safe.

Triglyceride is a fat storing and transporting energy. Excess energy, not only from fatty foods, can be stored as triglyceride. Excess carbohydrates, alcohol, insulin resistance and uncontrolled diabetes can contribute to high levels. [1, 15]

LDL and HDL are not two different cholesterol molecules; they are different lipoprotein particles carrying cholesterol. VLDL particles transport triglyceride from the liver. Cholesterol in VLDL and remnant particles also contributes to vascular risk. “Good” and “bad” are memorable terms but do not describe all the biology. [2]

Why Does LDL Matter, and Why Does HDL Not Solve Everything?

LDL-containing atherogenic particles may enter and remain in vessel walls, leading to inflammation and plaques. Risk depends not only on today’s value but on how high the exposure is and how long it lasts . Years of high LDL from a young age matter even with a low short-term risk estimate. The general framework is described in our cardiovascular disease risk factors article. [1, 7]

HDL participates in transporting cholesterol back from tissues. However, measured HDL-C does not directly assess these functions. Raising the number alone does not automatically reduce heart attack risk; current care is not based on pharmacologically raising HDL. [3]

Some large observational studies report U-shaped relationships between very high HDL and mortality. This does not prove high HDL itself is harmful or should be lowered; it shows that “the higher, the better” is inadequate as a principle. Starting alcohol to raise HDL is not recommended. [4, 22]

What Should General Adult Values Be?

The tables below are general classifications used to read adult reports. All values are in mg/dL. Especially for LDL, an “acceptable” laboratory result may not mean adequate treatment in someone at high risk.

Total cholesterol and HDL should be considered together: some total cholesterol may be carried in HDL. But the total/HDL ratio alone is insufficient; LDL, non-HDL and, if needed, ApoB are assessed separately. [3, 5, 15, 25]

This classification is a descriptive table; the risk targets below indicate intended treatment levels. They should not be used interchangeably. [6, 18]

The Current Answer to “What Is My LDL Target for My Age?”

There is no table automatically raising the permitted LDL limit with age. Of two people the same age, one may be healthy while the other has had a heart attack, diabetes or kidney disease. Their targets therefore differ.

The 2025 ESC/EAS update retains European risk-based LDL targets. The following visual summarizes them. Physicians determine risk category, not age or one blood value alone. [9, 10]

The 2026 ACC/AHA guideline also reemphasizes absolute LDL and non-HDL targets: for primary prevention at borderline/moderate risk, LDL <100; high risk <70; very-high-risk known atherosclerotic cardiovascular disease <55 mg/dL. US and European risk categories are not identical, so numbers must not be indiscriminately transferred between classifications. [8]

How Is Overall Risk Calculated?

Smoking, blood pressure, diabetes, kidney function, known vascular disease and family history are assessed together. The US 2026 guideline uses PREVENT-ASCVD for suitable people; Europe uses SCORE2/SCORE2-OP. These were developed for different populations. In Turkey, interpretation requires appropriate regional assessment. Coronary calcium scoring may help selected uncertain cases; routine tomography is unnecessary for everyone. [8, 9]

Child and Adolescent Values Differ from Adults

High cholesterol in children is not solely due to excess weight. Hereditary conditions such as familial hypercholesterolemia can occur in lean, active children. Early diagnosis may enable assessment of parents and siblings as well. [11]

These are NHLBI-based pediatric/adolescent thresholds in mg/dL. Age distinctions are particularly important for triglycerides: A value below 150 in adults may be high in children. One high reading does not directly imply medication; repeat testing, family history, secondary causes and, if needed, a pediatric lipid specialist assessment are required. [12, 13]

When Should Children Be Tested?

The 2026 ACC/AHA recommends testing all previously unscreened children at ages 9–11 . With familial hypercholesterolemia, very high cholesterol or premature vascular disease in the family, from approximately age 2 selective screening may be considered. The established NHLBI/AAP pediatric approach also includes ages 17–21 as a second screening window, planned alongside transition to adult screening. [11, 13]

Limits of the Evidence: Not all institutions agree. In its 2023 assessment, USPSTF found insufficient direct evidence on long-term benefits versus harms of screening all asymptomatic children. This does not mean children with family history or high risk should not be assessed; it reflects differing interpretations of universal screening evidence. [14]

Triglycerides: When Is It Heart Risk, and When Pancreatitis Risk?

High triglycerides often accompany insulin resistance, diabetes, excess energy intake and fatty liver. Remnants of triglyceride-rich lipoproteins and their cholesterol also matter for cardiovascular risk. With very high triglycerides, pancreatic inflammation (acute pancreatitis) becomes a separate treatment priority. [2, 15]

These thresholds are not sharp biological walls where risk suddenly begins. Nonfasting TG ≥175 mg/dL may be considered elevated. With very high TG, severe upper abdominal pain, pain radiating to the back or vomiting requires urgent assessment. An asymptomatic high result should not be left unchecked for months; promptly consult a physician. [15, 16]

How Is Total Cholesterol Measured and LDL Calculated?

In a lipid panel, total cholesterol, HDL and triglycerides are generally measured in the laboratory; LDL may be calculated or directly measured depending on method. The older expression “total cholesterol = LDL + HDL + TG/5” is a rearrangement of a classic LDL calculation rather than a definition of total cholesterol.

The Friedewald formula must not be used when TG ≥400 mg/dL; being below 400 does not guarantee accuracy in every circumstance. Error may be substantial with low LDL and increased TG. Laboratories may use newer equations such as Martin–Hopkins or Sampson. When results differ, first check method and fasting status. [17]

What Happens If mg/dL and mmol/L Are Confused?

To convert cholesterol from mg/dL to mmol/L, divide by approximately 38,67; to convert triglycerides, divide by 88,57 . The same factor cannot be used for both. For example, LDL 100 mg/dL is approximately 2,59 mmol/L; TG 150 mg/dL is approximately 1,69 mmol/L. Comparing reports without units may mislead. [17, 18]

Fasting or Nonfasting, and How Often?

Initial lipid assessment can often be nonfasting. However, marked TG elevation—for example ≥400 mg/dL in a nonfasting sample—known/suspected severe triglyceride disorders or special circumstances require a fasting panel. Follow laboratory/physician instructions for fasting duration and medication.

In the 2026 ACC/AHA approach, adult screening starts at age 19 and repeats at least every five years ; extra risk, high values or treatment require more frequent testing. After starting medication or changing dose, usually within 4–12 weeks response is assessed; subsequent intervals depend on target, treatment and risk. Screening frequency differs from medication follow-up frequency. [7, 18]

ApoB and Lp(a): What Can We Learn Beyond the Standard Panel?

ApoBindicates atherogenic particle numbers, while LDL-C measures their cholesterol. Especially in diabetes, high TG and metabolic disorders, LDL may appear low despite many particles. ApoB and non-HDL help assess this discordance; extensive advanced testing is not necessary for everyone. [25]

Lipoprotein(a), or Lp(a), is a largely inherited independent risk factor. The 2026 guideline recommends measurement at least once in adult life. Values ≥125 nmol/L or ≥50 mg/dL are associated with increased risk. These are thresholds in different units; a fixed conversion factor must not be applied to Lp(a). High results prompt closer LDL and other risk management and, when needed, family assessment. [19]

Why Does Cholesterol Rise? Why Is Weight Alone Insufficient?

A lean person may have very high LDL genetically. An overweight person’s lipids are not always equally disturbed. Insulin resistance and metabolic fatty liver may particularly accompany high TG/low HDL; body appearance does not replace a blood test.

High results require consideration of hypothyroidism, uncontrolled diabetes, nephrotic syndrome/kidney disease, cholestasis, pregnancy, alcohol and medications. TSH, glucose/HbA1c, kidney and liver tests may be requested. Corticosteroids, certain retinoids and immunosuppressants may affect lipids. Correcting secondary causes matters but does not mean delaying necessary treatment at high vascular risk. [15, 20]

When Should Familial Hypercholesterolemia Be Suspected?

Persistent adult LDL ≥190 mg/dL, very high LDL at a young age, family premature heart attack or similar cholesterol elevation requires assessment. Waiting based only on short-term risk scores may be inappropriate. Close relatives should be screened. Healthy eating alone cannot always correct an inherited LDL clearance problem. [11, 18]

What Helps in Nutrition?

Neither “fatty foods never affect cholesterol” nor “all fats are harmful” is correct. The type of fat and what replaces it matter. Replacing saturated with unsaturated fat benefits LDL. Replacing it with sugar and refined flour does not provide the same benefit. Dietary cholesterol responses vary; assess the entire diet. [21, 22]

For a dietary framework, see the health effects of the Mediterranean diet; for fiber benefits and limits, fibermaxxing and appropriate fiber consumption in our articles. Movement aims at overall health, not just a higher HDL number. To quit smoking, effective smoking cessation methods are described in our guide. [21, 22]

When Is Medication Needed, and Which Treatments Are Used?

Medication decisions depend on known vascular disease, LDL, diabetes/kidney disease and overall risk. Lifestyle measures continue throughout treatment. Needing medication to reach target, especially at high risk, does not indicate personal failure.

The 2025 ESC/EAS separately considers outcome data in selected high/very-high-risk patients with elevated TG despite statins for icosapent ethyl . This does not mean every commercially sold fish oil supplement offers the same benefit. For drug history, read the discovery of statins in our article. [9, 25]

Does Lowering LDL Provide Real Clinical Benefit?

In the CTT meta-analysis of approximately 170.000 participants in 26 randomized trials, each LDL reduction of 1 mmol/L (approximately 38,7 mg/dL)was associated with approximately 22% relative reduction in major vascular events. Not every patient receives the same absolute benefit; higher initial risk means more potentially preventable events. [23]

Practical Decision Flow Based on the Report

This flow does not prescribe treatment; it shows which question to address first.

Special Issues in Older Age, Pregnancy and Cancer Treatment

In older age, decisions depend not only on age but existing vascular disease, frailty, life expectancy, medication burden and personal priorities. “High cholesterol is acceptable in older people, no treatment needed” is incorrect, but maximum-intensity treatment is not automatically chosen for everyone either.

Pregnancy and breastfeeding plans must be disclosed. Lipids may change physiologically during pregnancy. Most pregnant women do not use statins; FDA removal of the absolute contraindication does not recommend routine pregnancy use. Specialists assess exceptional very-high-risk situations. [7, 24]

During cancer treatment, steroids and some systemic therapies may affect lipids or glucose. Interactions with statins and other drugs may occur. Rather than independently stopping cholesterol treatment, oncology and relevant physicians should plan together. Active treatment, nutritional problems and life expectancy may change prevention priorities. [20, 25]

Frequently Asked Questions

My LDL Fell; Can I Stop Medication?

The reduction may reflect treatment. Stopping may raise it again. Reaching target does not make therapy unnecessary; continuation or change is decided during follow-up.

Must I Stop Statins Completely If I Have Muscle Pain?

Other causes, interactions and appropriate tests are assessed. Drug, dose or combinations may change. Severe weakness and dark urine require rapid assessment. One experience does not mean all LDL-lowering options are unusable. [18]

My Cholesterol Is High but I Have No Symptoms—Does It Matter?

Yes. High LDL often causes no symptoms, while vascular damage develops over time. Headache or dizziness cannot reliably predict cholesterol. [1]

Can Eggs, Lemon Water or One Food Solve It?

Assess the whole diet and individual response rather than one food. Lemon water and similar practices do not replace necessary lipid-lowering treatment. Common misunderstandings are also discussed in what you should know about cholesterol in our article. [22]

Five Questions to Clarify with Your Physician

1. What are my overall cardiovascular risk and LDL/non-HDL target?
2. Could there be a genetic or treatable secondary cause?
3. Do I need repeat fasting measurement, ApoB or once-in-a-lifetime Lp(a)?
4. Besides lifestyle changes, is medication needed, and what is the expected absolute benefit?
5. When will testing be repeated, and whom should I contact about side effects?

For a broader review plan, our health check guide by age and personal risk may help.

Scientific References

Source check: 8 September 2026. Numbers correspond to the references below. Tables inform patients; individual treatment requires risk assessment. Research data and educational calculations are separately marked.

1. NHLBI. What is Blood Cholesterol?
2. Feingold KR. Introduction to Lipids and Lipoproteins. Endotext.
3. AHA. What Your Cholesterol Levels Mean. Updated: March 2026.
4. Madsen CM et al. Extreme high HDL cholesterol and mortality: two prospective cohort studies. European Heart Journal, 2017.
5. MedlinePlus. Cholesterol Levels: What You Need to Know.
6. MedlinePlus. LDL: The Bad Cholesterol.
7. Blumenthal RS et al. 2026 ACC/AHA Guideline on the Management of Dyslipidemia. Circulation.
8. ACC. Updated Guideline for Managing Lipids, Cholesterol. 13 March 2026.
9. Mach F et al. 2025 Focused Update of the 2019 ESC/EAS Dyslipidaemias Guidelines. European Heart Journal.
10. ESC. Cardiovascular Health Check: LDL targets by risk group.
11. ACC. No Child Left Behind: The Case For Early Lipid Screening. May 2026.
12. AHRQ/NCBI. Screening for Lipid Disorders in Children and Adolescents: Evidence Update, Table 4. 2023.
13. NHLBI Expert Panel. Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents.
14. USPSTF. Lipid Disorders in Children and Adolescents: Screening. 2023.
15. ACC. Consensus on ASCVD Risk Reduction in Hypertriglyceridemia. 2021.
16. NLA. Practical Approaches to Dietary Management of Hypertriglyceridemia.
17. Sampson M et al. Modified Sampson–NIH Equation with Improved Accuracy for LDL-C. Clinical Chemistry, 2025.
18. Endotext. Guidelines for the Management of Dyslipidemia. Updated: May 2026.
19. ACC. How the 2026 Dyslipidemia Guideline Changes Practice. July 2026.
20. StatPearls. Hypercholesterolemia — secondary causes.
21. AHA. Fats in Foods. January 2026.
22. Lichtenstein AH et al. 2026 Dietary Guidance to Improve Cardiovascular Health. Circulation.
23. Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: 26 trials, 170.000 participants. Lancet, 2010.
24. FDA. Statins during pregnancy: most patients should stop; individualized exceptions.
25. ACC. Getting to Goals: Applying the 2026 Dyslipidemia Guideline in High-Risk Patients. September 2026.